UNSPSC 51312603: Antazoline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DHA8014SS1, chemically known as 4,5-dihydro-n-phenyl-n-phenylmethyl-1h-imidazole-2-methanamine but generally known as antazoline, which bears US NIH Compound Identifier 2200. Antazoline most often comes in base, 7-theophyllineacetate, hydrochloride, mesylate, methanesulfonate, nitrate, and phosphate forms.

UNSPSC 51312603 Antazoline is a Commodity code that in recent state and local activity covers procurement of pharmaceutical products and medical supplies for public health initiatives, though recent opportunities tagged to this code involve naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than antazoline specifically. State and local governments soliciting under this code include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions. Issuing bodies range from individual counties managing community health procurement to state-level purchasing offices coordinating statewide or multi-state pharmaceutical supply agreements, with cooperative purchasing vehicles enabling cost management and standardized sourcing across multiple public entities.

Geographic activity centers on Florida and Minnesota, with Texas participating through exploratory procurement mechanisms. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS, an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance's S1070000015802, an RFP posted January 20, 2026, with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon; and the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs as a precursor to formal procurement. Pharmaceutical procurement under this code typically requires vendor compliance with FDA requirements, cGMP certification, Drug Supply Chain Security Act adherence, and established wholesaler relationships, with contracts structured around multi-year terms and volume-based pricing models.